PMV Pharmaceuticals Inc. (PMVP): Price and Financial Metrics
PMVP Price/Volume Stats
| Current price | $1.62 | 52-week high | $9.72 |
| Prev. close | $1.61 | 52-week low | $1.18 |
| Day low | $1.58 | Volume | 464,000 |
| Day high | $1.66 | Avg. volume | 548,591 |
| 50-day MA | $1.69 | Dividend yield | N/A |
| 200-day MA | $3.65 | Market Cap | 83.34M |
PMVP Stock Price Chart Interactive Chart >
PMV Pharmaceuticals Inc. (PMVP) Company Bio
PMV Pharmaceuticals, Inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations. PMV Pharmaceuticals, Inc. was formerly known as PJ Pharmaceuticals, Inc. and changed to in July 2013. The company was founded in 2013 and is headquartered in Cranbury, New Jersey.
Latest PMVP News From Around the Web
Below are the latest news stories about PMV PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PMVP as an investment opportunity.
PMV Pharmaceuticals Inc (PMVP) Reports Q3 2023 Financial Results and Corporate UpdatesKey Clinical Progress and Financial Metrics |
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate HighlightsUpdated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tumor types with median duration of response of seven monthsAn overall response rate of 38% observed at the recommended Phase 2 dose of 2000 mg daily for the intended Phase 2 population of TP53 Y220C and KRAS wild-type patientsRegistrational Phase 2 clinical trial expected to initiate in Q1 2024O |
PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for PMV Pharmaceuticals, Inc. (PMVP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C MutationUpdated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsConfirmed responses observed in multiple tumor types including ovarian, breast, prostate, lung, and endometrial cancer with median duration of response of seven monthsConfirmed overall response rate of 38% at Recommended Phase 2 Dose of 2000 mg daily (6/16 evaluable patients) reflective of the planned Phase 2 patient population (TP53 Y |
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL WebinarPRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it will present updated Phase 1 data from the ongoing Phase 1/2 PYNNACLE study of PC14586 in a late-breaking poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, i |
PMVP Price Returns
| 1-mo | -2.99% |
| 3-mo | 0.62% |
| 6-mo | 8.72% |
| 1-year | -66.11% |
| 3-year | -94.82% |
| 5-year | N/A |
| YTD | -47.74% |
| 2023 | -64.37% |
| 2022 | -62.34% |
| 2021 | -62.45% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...